Authors

Latest:

Dr. Doug Lowy on Preventing Cancer Through Vaccination

Douglas R. Lowy, MD, acting director, National Cancer Institute, chief, Laboratory of Cellular Oncology, senior Investigator, Head, Signaling and Oncogenesis Section, discusses vaccines that may show efficacy in certain tumor types.

Douglas Yee, MD

Latest:

Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Dr. Adam Bass

Latest:

Dr. Adam Bass on the Origins of Different Gastric Tumor Types

Dr. Adam Bass, MD, Dana-Farber Cancer Institute, discusses the causes for different types of gastric cancer.

Dr. George Somlo, MD

Latest:

Dr. George Somlo on Advances in Multiple Myeloma

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. Hisham Mehanna

Latest:

Dr. Hisham Mehanna on Quality of Life Differences in Head and Neck Squamous Cell Cancer

Hisham Mehanna, MBChB, PhD, Chair, Head and Neck Surgery, Director, Institute of Head and Neck Studies and Education at University of Birmingham, discusses differences in the quality of life (QoL) and functional outcomes of treatment between HPV-positive and HPV-negative head and neck squamous cell cancer patients (HNSCC).

Dr. Jordi Bruix, MD

Latest:

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Dr. Navesh K. Sharma

Latest:

Dr. Navesh K. Sharma on Older Patients Tolerating Internal Radiation

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses that age should not be a deciding factor in giving internal radiation to patients with liver cancer.

Dr. Peter Kufer, Vice President & Innovator of BITE Technology, Amgen Sponsored by Amgen Oncology

Latest:

BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches

Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.

Dr. Volker Heinemann, MD, PhD

Latest:

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

Dr. Yael Cohen

Latest:

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Drew Moghanaki, MD, MPH

Latest:

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Panelists discuss how financial toxicity and cost-effectiveness analyses highlight the importance of appropriate patient selection for perioperative immunotherapy, while emphasizing that multidisciplinary care and patient involvement remain essential for optimal outcomes.

Drug Discovery

Dung T. Le, MD

Latest:

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dungsa Chen PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dustin A. Deming, MD

Latest:

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Dustin Deming, MD, University of Wisconsin

Dustin M. Walters, MD

Latest:

Dr. Walters on the Best Approach to Treating Patients With Stage III Lung Cancer

Dustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.

Dwight L. Fitch, MD

Latest:

Dr. Fitch Discusses Dose Escalation of Radiation in Prostate Cancer

Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.

Dylann Cohn-Emery

Latest:

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

E. David Crawford, MD

Latest:

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.